A spokesperson for the health ministry stated that the Health Department was not affected by irbesartan’s recall from the market.
Replying to questions by Newsbook.com.mt, the Department’s spokesperson clarified that the Department does not purchase irbestan thus it was not affected by the recall issue. UK pharmacies were ordered to recall certain irbesartan containing medications made by Actavis (Accord) as a precautionary measure, due to possible N-nitrosodiethylamine (NDEA) contamination.
Irbesartan is a high blood pressure medicine.
In November 2018, Valsartan Mylan, a high blood pressure medicine, was recalled from the market after the European Medcines Agency issued a set of updated recommendations on the medicine.